Meningococcal infection is a bacterial infection caused by Neisseria meningitidis, also known as meningococcus, a gram-negative bacterium. Meningococcal meningitis is a serious infection of the thin lining that surrounds the brain and spinal cord.
Furthermore, according to the World Health Organization Meningococcal meningitis is observed worldwide but the highest burden of the disease is in the meningitis belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30,000 cases are still reported each year from that area.
Market Dynamics
The global meningococcal disease treatment market is expected to witness significant growth during the forecast period owing to the increasing prevalence of meningococcal disease. According to the centers for disease control and prevention, there were about 330 total cases of meningococcal disease reported in the U.S. in 2018.
Key features of the study:
- This report provides in-depth analysis of the global meningococcal disease treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global meningococcal disease treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are GlaxoSmithKline Plc., Novartis AG, Sanofi Pasteur Inc., Wockhardt Ltd., Kent Pharmaceuticals, Stravencon Limited., F. Hoffmann-La Roche Ltd., Athlone Laboratories, and Pfizer Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global meningococcal disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global meningococcal disease treatment market
Detailed Segmentation:
- Global Meningococcal Disease Treatment Market, By Therapy Type:
- Antibiotics
- Penicillin
- Ampicillin
- Chloramphenicol
- Ceftriaxone
- Vaccines
- Bivalent
- Trivalent
- Tetravalent
- Global Meningococcal Disease Treatment Market, By Route of Administration:
- Global Meningococcal Disease Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Global Meningococcal Disease Treatment Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- GlaxoSmithKline Plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis AG
- Sanofi Pasteur Inc.
- Wockhardt Ltd.
- Kent Pharmaceuticals
- Stravencon Limited.
- Hoffmann-La Roche Ltd.
- Athlone Laboratories
- Pfizer Inc.
“*” marked represents similar segmentation in other categories in the respective section.
